Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria

Journal of Controlled Release

Volumn 222, Issue , 2016, Pages 9-17

  Lehouritis, Panos ^a   Stanton, Michael ^a   McCarthy, Florence O ^b   Jeavons, Matthieu ^a   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cancer; Chemotherapy; GDEPT; Targeting; Therapy

Indexed keywords

BACTERIA; CHEMICAL ACTIVATION; CHEMOTHERAPY; ENZYME ACTIVITY; ENZYMES; ESCHERICHIA COLI; MAMMALS; METADATA; TUMORS;

BIOCHEMICAL TRANSFORMATION; CANCER; CHEMOTHERAPEUTIC DRUGS; GDEPT; GENETIC MODIFICATIONS; SYSTEMIC ADMINISTRATION; TARGETING; THERAPY;

ACTIVATION ANALYSIS;

BANOXANTRONE; FLUCYTOSINE; FLUDARABINE PHOSPHATE; PROBIOTIC AGENT; PRODRUG; TRETAZICAR; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; BACTERIAL PROTEIN; ENZYME; VIDARABINE PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM CULTURE; BIFIDOBACTERIUM BREVE; BIOTRANSFORMATION; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LACTOBACILLUS; LACTOCOCCUS LACTIS; MALE; MAMMAL CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; SCREENING; TISSUE CULTURE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYMOLOGY; LACTOCOCCUS; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; AZIRIDINES; BACTERIAL PROTEINS; BIFIDOBACTERIUM; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENZYMES; ESCHERICHIA COLI; FEMALE; LACTOBACILLUS; LACTOCOCCUS; MICE, INBRED BALB C; NEOPLASMS; PROBIOTICS; PRODRUGS; TUMOR BURDEN; VIDARABINE PHOSPHATE;

EID: 84949870540     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.11.030     Document Type: Article

References (27)

1. J. Cummins, and M. Tangney Bacteria and tumours: causative agents or opportunistic inhabitants? Infect. Agent Cancer 8 2013 11
2. D. Morrissey, G.C. O'Sullivan, and M. Tangney Tumour targeting with systemically administered bacteria Curr. Gene Ther. 10 2010 3 14
3. C.K. Baban, M. Cronin, D. O'Hanlon, G.C. O'Sullivan, and M. Tangney Bacteria as vectors for gene therapy of cancer Bioeng. Bugs 1 2010 385 394
4. M. Zhao, M. Yang, X.M. Li, P. Jiang, E. Baranov, S. Li, M. Xu, S. Penman, and R.M. Hoffman Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium Proc. Natl. Acad. Sci. U. S. A. 102 2005 755 760
5. J. Stritzker, P.J. Hill, I. Gentschev, and A.A. Szalay Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice Bioeng. Bugs 1 2010 139 145
6. N.P. Minton Clostridia in cancer therapy Nat. Rev. Microbiol. 1 2003 237 242
7. V.H. Nguyen, H.S. Kim, J.M. Ha, Y. Hong, H.E. Choy, and J.J. Min Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer Cancer Res. 70 2010 18 23
8. J. Nemunaitis, C. Cunningham, N. Senzer, J. Kuhn, J. Cramm, C. Litz, R. Cavagnolo, A. Cahill, C. Clairmont, and M. Sznol Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients Cancer Gene Ther. 10 2003 737 744
9. N.J. Roberts, L. Zhang, F. Janku, A. Collins, R.Y. Bai, V. Staedtke, A.W. Rusk, D. Tung, M. Miller, J. Roix, K.V. Khanna, R. Murthy, R.S. Benjamin, T. Helgason, A.D. Szvalb, J.E. Bird, S. Roy-Chowdhuri, H.H. Zhang, Y. Qiao, B. Karim, J. McDaniel, A. Elpiner, A. Sahora, J. Lachowicz, B. Phillips, A. Turner, M.K. Klein, G. Post, L.A. Diaz Jr., G.J. Riggins, N. Papadopoulos, K.W. Kinzler, B. Vogelstein, C. Bettegowda, D.L. Huso, M. Varterasian, S. Saha, and S. Zhou Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses Sci. Transl. Med. 6 2014 249ra111
10. R.A. Spooner, F. Friedlos, K. Maycroft, S.M. Stribbling, J. Roussel, J. Brueggen, B. Stolz, T. O'Reilly, J. Wood, A. Matter, R. Marais, and C.J. Springer A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs Br. J. Cancer 88 2003 1622 1630
11. C.J. Springer, and I.I. Niculescu-Duvaz Antibody-directed enzyme prodrug therapy (ADEPT): a review Adv. Drug Deliv. Rev. 26 1997 151 172
12. S. Schepelmann, L.M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, P. Chen, R. Marais, and C.J. Springer Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2 Cancer Res. 67 2007 4949 4955
13. P. Lehouritis, C. Springer, and M. Tangney Bacterial-directed enzyme prodrug therapy J. Control. Release 170 2013 120 131
14. C. Cunningham, and J. Nemunaitis A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001 Hum. Gene Ther. 12 2001 1594 1596
15. F. Friedlos, P. Lehouritis, L. Ogilvie, D. Hedley, L. Davies, D. Bermudes, I. King, J. Martin, R. Marais, and C.J. Springer Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy Clin. Cancer Res. 14 2008 4259 4266
16. M. Cronin, D. Morrissey, S. Rajendran, S.M. El Mashad, D. van Sinderen, G.C. O'Sullivan, and M. Tangney Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors Mol. Ther. 18 2010 1397 1407
17. M. Cronin, A.R. Akin, S.A. Collins, J. Meganck, J.B. Kim, C.K. Baban, S.A. Joyce, G.M. van Dam, N. Zhang, D. van Sinderen, G.C. O'Sullivan, N. Kasahara, C.G. Gahan, K.P. Francis, and M. Tangney High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting PLoS One 7 2012 e30940
18. M. Cronin, F. Le Boeuf, C. Murphy, D.G. Roy, T. Falls, J.C. Bell, and M. Tangney Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy Mol. Ther. 22 2014 1188 1197
19. M. Tangney Gene therapy for cancer: dairy bacteria as delivery vectors Discov. Med. 10 2010 195 200
20. A. Valle, S. Le Borgne, J. Bolivar, G. Cabrera, and D. Cantero Study of the role played by NfsA, NfsB nitroreductase and NemA flavin reductase from Escherichia coli in the conversion of ethyl 2-(2′-nitrophenoxy)acetate to 4-hydroxy-(2H)-1,4-benzoxazin-3(4H)-one (D-DIBOA), a benzohydroxamic acid with interesting biological properties Appl. Microbiol. Biotechnol. 94 2012 163 171
21. K.D. Somers, R.R. Brown, D.A. Holterman, N. Yousefieh, W.F. Glass, G.L. Wright Jr., P.F. Schellhammer, J. Qian, and R.P. Ciavarra Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy Int. J. Cancer 107 2003 773 780
22. S. Ahmad, G. Casey, P. Sweeney, M. Tangney, and G.C. O'Sullivan Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth Mol. Ther. 17 2009 1101 1108
23. S.O. Vass, D. Jarrom, W.R. Wilson, E.I. Hyde, and P.F. Searle E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954 Br. J. Cancer 100 2009 1903 1911
24. N.A. Helsby, D.M. Ferry, A.V. Patterson, S.M. Pullen, and W.R. Wilson 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT Br. J. Cancer 90 2004 1084 1092
25. G.A. Prosser, J.N. Copp, S.P. Syddall, E.M. Williams, J.B. Smaill, W.R. Wilson, A.V. Patterson, and D.F. Ackerley Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 Biochem. Pharmacol. 79 2010 678 687
26. W.B. Parker, S.A. King, P.W. Allan, L.L. Bennett Jr., J.A. Secrist 3rd, J.A. Montgomery, K.S. Gilbert, W.R. Waud, A.H. Wells, G.Y. Gillespie, and E.J. Sorscher In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase Hum. Gene Ther. 8 1997 1637 1644
27. E.A. Austin, and B.E. Huber A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase Mol. Pharmacol. 43 1993 380 387